Table 2.
Characteristic | Total (N=364) | Antipsychotic Monotherapy (N=294) | Antipsychotic Polypharmacy (N=70) | F/chi2 | P-value |
---|---|---|---|---|---|
Metabolic syndrome (N, %) | 136 (37.4) | 101 (34.3) | 35 (50.0) | χ2: 5.91 | 0.015 |
# of metabolic syndrome criteria (±SD) | 1.97± 1.3 | 1.9 ± 1.4 | 2.2 ± 1.4 | F: 1.81 | 0.18 |
Waist circumference >102 cm in males or >88 cm in females (N, %) | 122 (33.5) | 94 (32.0) | 28 (40.0) | χ2: 1.63 | 0.20 |
Triglycerides ≥150 mg/dL (N, %)a | 151 (41.6) | 117(39.8) | 34 (49.3) | χ2: 2.07 | 0.15 |
Fasting hyperglycemia ≥110 mg/dL (N, %)b | 42 (11.6) | 35 (11.9) | 7(10.1) | χ2: 0.18 | 0.67 |
Hypertension 130/85 mm Hg (N, %) | 173 (47.5) | 139 (47.3) | 34 (48.6) | χ2: 0.038 | 0.85 |
HDL <40 mg/dl in males or <50 mg/dl in females (N, %) | 212 (58.2) | 163 (55.4) | 49 (70.0) | χ2: 4.93 | 0.026 |
Triglyceride/HDL-cholesterol >3.5 (N, %)a | 138 (38.0) | 103 (35.0) | 35 (50.7) | χ2: 5.84 | 0.016 |
Continuous Metabolic Variables | |||||
Waist circumference (cm±SD) | 92.2 ± 14.2 | 91.4 ± 13.7 | 95.5 ± 16.1 | F: 4.84 | 0.028 |
Fasting glucose (mg/dL±SD)b | 93.1 ±22.5 | 92.6 ± 22.0 | 95.0 ± 24.6 | F: 0.65 | 0.42 |
Systolic blood pressure (mm Hg±SD) | 124.0 ± 14.7 | 123.8 ± 14.3 | 124.9 ± 16.6 | F: 0.32 | 0.75 |
Diastolic blood pressure (mm Hg±SD) | 79.0 ±9.1 | 78.8 ± 9.0 | 79.9 ± 9.7 | F: 0.91 | 0.34 |
HDL (mg/dl ±SD) | 44.8 ± 12.1 | 45.2 ± 12.3 | 42.9 ± 10.9 | F: 2.09 | 0.15 |
Triglycerides (mg/dL±SD)a | 136.2 ±81.8 | 134.2 ±81.3 | 144.6 ± 83.8 | F: 0.91 | 0.34 |
Total cholesterol (mg/dL±SD)a | 171.4 ±40.1 | 172.5 ± 39.5 | 167.0 ±42.3 | F: 01.06 | 0.30 |
LDL-cholesterol (mg/dL±SD)a | 115.5 ±37.2 | 115.7 ±36.6 | 114.9 ±39.5 | F: 0.03 | 0.87 |
Triglyceride/HDL-cholesterol ratio (±SD)a | 3.5 ±2.8 | 3.4 ±2.8 | 3.7 ±2.5 | F: 0.70 | 0.4 |
: Based on 363 patients with available information;
: based on 362 patients with available information